2004
DOI: 10.1186/1475-2867-4-6
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Background: Heptaplatin is a new platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant cancer cell lines (Cancer Chemother Pharmacol 1995; 35: 441).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
13
0

Year Published

2007
2007
2018
2018

Publication Types

Select...
6
2
2

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(13 citation statements)
references
References 31 publications
0
13
0
Order By: Relevance
“…The plates were held for 5 min at room temperature with shaking in order to completely dissolve formazan. The absorbance of the MTT formazan was determined at 540 nm using a UV-spectrophotometric plate reader ( Choi et al ., 2004 ).…”
Section: Methodsmentioning
confidence: 99%
“…The plates were held for 5 min at room temperature with shaking in order to completely dissolve formazan. The absorbance of the MTT formazan was determined at 540 nm using a UV-spectrophotometric plate reader ( Choi et al ., 2004 ).…”
Section: Methodsmentioning
confidence: 99%
“…The absorbance of the MTT formazan was determined at 540 nm using a UV-spectrophotometric plate reader (Choi et al , 2004).…”
Section: Methodsmentioning
confidence: 99%
“…Thus the application of the drug is restricted to a relatively narrow class of tumors and the efforts were focused on the design of new platinum compounds with broader spectrum of antitumor activity and improved pharmacological properties with respect to toxicity and resistance. Several complexes structurally related to cis -platin, such as oxaliplatin and carboplatin, nedaplatin (Japan), lobaplatin (China), heptaplatin (South Korea) [ 5 , 13 , 14 ], are currently in clinical trials and use, but till now they have not demonstrated significant advantages over cis -platin. It seems possible that the complex structural analogs of cis -platin designed on the basis of structure-activity relationships [ 15 ] could scarcely offer serious advantages over the existing drugs.…”
Section: Introductionmentioning
confidence: 99%